Biomarkers
MET Exon 14 Skipping
Also known as: MET exon 14 mutation, METex14, MET splice site mutation
Definition
A mutation causing deletion of MET exon 14, leading to MET activation and targetability with MET inhibitors.
Detailed Explanation
MET ex14 skipping occurs in 3-4% of NSCLC, more common in older patients and sarcomatoid histology. Causes MET protein stabilization and oncogenic signaling. Treated with MET inhibitors like capmatinib (Tabrecta) and tepotinib (Tepmetko). Can also develop as resistance mechanism to EGFR inhibitors.